Comparative Analysis Of Dexmedetomidine And Dexamethasone As An Adjuvant To 0.5%Ropivacaine On Onset Of Ultrasound Guided Supraclavicular Brachial Plexus Block In Patients Undergoing Upper Limb Surgeries

Recruiting Phase 2 Phase 3 Interventional Study
Post Operative Analgesia Bradycardia Hypotension Upper Limb Surgeries
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 70
Sex
Any
Trial phase
Phase 2/3
Study type
Interventional
Purpose
Treatment
Participants needed
66 (estimated)
Sponsor
Sahiwal medical college sahiwal · Government
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
To compare the efficacy of dexmedetomidine and dexamethasone as an adjuvant to 0.5%ropivacaine on onset of ultrasound guided supraclavicular brachial plexus block in patients undergoing upper limb surgeries. Ropivacaine hydrochloride, a long acting local anesthetic, is commonly used for supraclavicular block owing to its favorable safety profile especially in terms of minimal cardiotoxicity and l…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria * Patients scheduled for upper limb surgery below mid-humerus level * Patients aged 18 to 70 years * Patients with ASA class I, II and III * Male and non-pregnant females Exclusion Criteria * Patients refusal * Patients with pre-existing peripheral neuropathy of the upper limb * …
Contacts

Dr Maryam Maqsood, MBBS

00923347036271

maryammaqsood448@gmail.com

CONTACT

Dr Muhammad Shahid, FCPS

00923336173056

shahidnishtar@gmail.com

CONTACT